uniQure (NASDAQ:QURE) Trading Down 5% - Here's What Happened

Key Points

• uniQure's stock fell 5% on Monday, trading at $15.38 after hitting a low of $15.51, with volume down significantly to 187,720 shares compared to an average of 1,387,123 shares.
• Several analysts have weighed in with a positive outlook, with target prices ranging from $28 to $70, resulting in a consensus rating of "Moderate Buy" and an average price target of $37.45.
• Recent insider trading reveals director Robert Gut sold 3,336 shares, reducing his ownership by 5.54%, alongside other sales by insiders totaling 22,144 shares in the past 90 days.

Shares of uniQure N.V. (NASDAQ:QURE - Get Free Report) dropped 5% on Monday . The company traded as low as $15.51 and last traded at $15.38. Approximately 187,720 shares were traded during mid-day trading, a decline of 86% from the average daily volume of 1,387,123 shares. The stock had previously closed at $16.18.

Wall Street Analyst Weigh In

Several equities analysts have commented on QURE shares. HC Wainwright reiterated a "buy" rating and set a $70.00 price target on shares of uniQure in a report on Thursday, May 29th. Guggenheim reiterated a "buy" rating and issued a $28.00 target price on shares of uniQure in a report on Monday, May 12th. Cantor Fitzgerald set a $47.00 target price on shares of uniQure in a research report on Wednesday, July 30th. Wall Street Zen raised uniQure from a "sell" rating to a "hold" rating in a research report on Saturday, August 2nd. Finally, Chardan Capital cut their price objective on uniQure from $38.00 to $35.00 and set a "buy" rating for the company in a research report on Tuesday, July 29th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, uniQure presently has an average rating of "Moderate Buy" and a consensus price target of $37.45.

uniQure Stock Down 3.2%

The firm has a market capitalization of $859.26 million, a price-to-earnings ratio of -3.99 and a beta of 0.11. The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 9.98. The business has a 50 day moving average of $14.62 and a 200 day moving average of $13.62.

uniQure (NASDAQ:QURE - Get Free Report) last posted its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share for the quarter, beating analysts' consensus estimates of ($0.89) by $0.20. The business had revenue of $5.26 million for the quarter, compared to analysts' expectations of $5.00 million. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. On average, equities analysts anticipate that uniQure N.V. will post -3.75 EPS for the current year.

Insiders Place Their Bets

In other uniQure news, Director Robert Gut sold 3,336 shares of uniQure stock in a transaction on Friday, June 20th. The stock was sold at an average price of $14.45, for a total transaction of $48,205.20. Following the completion of the transaction, the director directly owned 56,879 shares of the company's stock, valued at approximately $821,901.55. This trade represents a 5.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jeannette Potts sold 4,670 shares of the business's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $15.14, for a total transaction of $70,703.80. Following the completion of the sale, the insider owned 115,073 shares in the company, valued at $1,742,205.22. This represents a 3.90% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 22,144 shares of company stock worth $322,426 in the last 90 days. 4.79% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On uniQure

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Invesco Ltd. boosted its holdings in shares of uniQure by 453.2% in the 4th quarter. Invesco Ltd. now owns 613,601 shares of the biotechnology company's stock worth $10,836,000 after acquiring an additional 502,684 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in uniQure by 355.2% in the first quarter. Assenagon Asset Management S.A. now owns 334,894 shares of the biotechnology company's stock worth $3,550,000 after purchasing an additional 261,323 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of uniQure during the fourth quarter worth $1,951,000. Northern Trust Corp increased its stake in shares of uniQure by 2.1% in the fourth quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company's stock valued at $1,688,000 after buying an additional 1,923 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of uniQure by 2.3% in the fourth quarter. Geode Capital Management LLC now owns 520,553 shares of the biotechnology company's stock valued at $9,198,000 after buying an additional 11,951 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.